好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Autoimmune disease-related primary CNS lymphoma: Review of literature and meta-analysis.
Neuro-oncology
P4 - Poster Session 4 (5:30 PM-6:30 PM)
13-006
We aimed to better define the clinical characteristics of autoimmune disease-related primary CNS lymphoma (PCNSL).

Recent studies suggest a relatively high prevalence of autoimmune disorders (AD) among PCNSL patients, however, the literature is limited to case reports. To gain a better understanding of AD-PCNSL we reviewed and analyzed all cases described in the literature. 

We mined the MEDLINE database using the search terms ‘central nervous system lymphoma’ or ‘CNS lymphoma’ along with AD-related terms. We selected 39 records for qualitative synthesis of data and identified 50 AD-PCNSL. Clinical, imaging and outcome data were collected. Overall survival (OS) was analyzed with the Kaplan-Meier method. Univariate and multivariate analyses were performed using logrank test and cox proportional hazard model. 

Most common AD were systemic lupus erythematosus (24%), multiple sclerosis (16%), and myasthenia gravis (14%). All patients had received immunosuppressants for their AD. Median interval from AD until PCNSL diagnosis was 108 months (range: 11-420). Male-to-female ratio was 0.42 and AD-PCNSL was diagnosed at a median age of 57 years (range: 2-88). On imaging lesions typically localized to the hemispheres (65%) and displayed peripheral enhancement (74%). Pathological evaluation revealed diffuse large-B-cell lymphoma (DLBCL) subtype (80%) and Epstein-Barr virus positivity (75%) in most AD-PCNSL. Median OS was 31 months. Age > 60 years (p=0.014) was identified as a significant prognostic factor. 

AD that often display severe inflammatory activity and hence require high dose immunosuppression appear over-represented in PCNSL. Clinical, pathological and radiological characteristics resemble other immunodeficiency-related PCNSL. Age >60 may serve as prognostic factors for AD-PCNSL. 

Authors/Disclosures
Leon D. Kaulen, MD
PRESENTER
Dr. Kaulen has nothing to disclose.
Philipp Karschnia Philipp Karschnia has nothing to disclose.
Jorg Dietrich, MD, PhD, FAAN Dr. Dietrich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Dietrich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ono Pharmaceuticals. Dr. Dietrich has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Johnson. Dr. Dietrich has received publishing royalties from a publication relating to health care.
Joachim M. Baehring, MD, FAAN (Yale University School of Medicine) Dr. Baehring has nothing to disclose.